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Eric Bartee,1 Winnie M. Chan,1 Jan S. Moreb,2 Christopher R. Cogle,2 Grant McFadden1Autologous stem cell transplantation and novel therapies have improved overall survival of patients with mul-
tiple myeloma; however, most patients relapse and eventually succumb to their disease. Evidence indicates
that residual cancer cells contaminate autologous grafts and may contribute to early relapses after autolo-
gous stem cell transplantation. Here, we demonstrate that ex vivo treatment with an oncolytic poxvirus
calledmyxoma virus results in specific elimination of human myeloma cells by inducing rapid cellular apoptosis
while fully sparing normal hematopoietic stem and progenitor cells. The specificity of this elimination is based
on strong binding of the virus to myeloma cells coupled with an inability of the virus to bind or infect CD341
hematopoietic stem and progenitor cells. These 2 features allow myxoma to readily identify and distinguish
even low levels of myeloma cells in complex mixtures. This ex vivo rabbit-specific oncolytic poxvirus called
myxoma virus treatment also effectively inhibits systemic in vivo engraftment of human myeloma cells into im-
munodeficient mice and results in efficient elimination of primary CD1381 myeloma cells contaminating pa-
tient hematopoietic cell products. We conclude that ex vivo myxoma treatment represents a safe and
effective method to selectively eliminate myeloma cells from hematopoietic autografts before reinfusion.
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stem cell transplantationINTRODUCTION
Multiplemyeloma (MM) is a clonal plasma cellma-
lignancy that is most prevalent in adults over the age of
65 and accounts for 10% to 15% of newly diagnosed
hematopoietic cancers with patients losing an average
of 17 years of life expectancy per diagnosis [1]. Al-
though recent clinical advances have improved the
prognosis for patients with MM, life expectancy at
diagnosis remains 2 to 5 years with a 5-year survival
rate of only 34% [2,3]. Currently, the standard of care
for patients with MM is treatment with high-dose che-
motherapy followed by autologous stem cell transplan-
tation (ASCT). In North America alone, ASCT is used1Department of Molecular Genetics and Microbiology;
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ally. This treatment results in improved rates of disease
remission as well as significantly prolonged event-free
survival time compared with patients treated with con-
ventional chemotherapy [4,5]. However, despite the
improved prognosis associated with myeloablative
chemotherapy followed by ASCT, the treatment is
generally not curative, and a large majority of all
patients with MM will suffer from relapsed disease.
The malignant cells that cause relapse are thought
to originate from 2 sources: residual MM cells, which
escape ablative therapy in bone marrow (BM) niches
and low levels of MM cells that contaminate the
autografts. To date, the relative impact of each of these
2 sources in causing MM relapse remains unclear;
however, several observations suggest that residual
plasma cell contamination plays a significant role. First,
it has been repeatedly reported that patients with MM
with lower levels of autograft contamination achieve
greater benefit from transplantation than patients
with higher levels of contamination [6-8]. Second,
patients undergoing syngeneic transplantation, using
uncontaminated BM from an identical twin donor,
routinely achieve better rates of complete remission,
improved long-term survival, and possibly even com-
plete cures [9-11]. These data, particularly the
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conclusion that even low levels of MM cells
contaminating the autograft can play a significant
role in disease relapse and suggest that ex vivo
manipulation of the autograft before infusion to
remove all contaminating malignant cells, a process
known as purging [12], could improve the outcomes
of patients with MM.
Proposed MM purging procedures must meet 2
important criteria: (1) they must effectively remove
all contaminating cancer cells from the grafts and (2)
they must fully spare the normal hematopoietic
stem/progenitor cells (HSPCs) in the autograft allow-
ing for successful reconstitution of the patient’s hema-
topoietic system. Several purging methods have been
explored in ASCT [13-16], including a recent study
focusing on ex vivo culture conditions that favor
survival of HSPCs [17]. For MM, most of the
focus has been placed on CD341 stem cell enrichment
[18-20], which can reduce the level of MM
contamination within the graft by 2 to 3 logs [20]. Un-
fortunately, clinical trials have demonstrated that this
CD34-based purging does not improve clinical out-
comes for patients with MM [19,21]. The results of
these trials were initially interpreted as proof that
myeloma relapse was primarily caused by residual
disease persisting in the patient after ablative
chemotherapy; however, subsequent molecular
studies have shown that low levels of contaminating
CD1381 MM cells remain in ASCT samples even
after multiple rounds of CD341 cell enrichment [22-
24]. Moreover, CD341 malignant MM clones have
been identified in patients which calls into questions
the utility of CD34 enrichment in these patients
[25,26]. Together, these data suggest that CD341
stem cell enrichment might fail to improve the
prognosis of patients with MM because disease-
causing MM cells remain in the autografts after
positive CD341 cell selection of peripheral blood
stem cells. Therefore, alternative means of ex vivo
purging must be explored [12].
Previously, our laboratory demonstrated that a rab-
bit-specific oncolytic poxvirus called myxoma virus
(MYXV) can eliminate primary acutemyeloid leukemia
cells from primary human BM samples while sparing
normal HSPCs [27]. MYXV is an attractive virothera-
peutic to target and eliminate human cancer cells for
several reasons. First, the virus does not elicit detectable
disease in any non-rabbit species, including humans or
severely immunocompromised mice [28,29]. Second,
the ex vivo therapeutic application of MYXV is not
dependent on expression of transgenes or addition of
chemotherapeutic agents and requires only a brief
ex vivo incubation of the graft with MYXV before
transplantation, thus making it an attractive strategy
for clinical administration that minimally deviates
from standard ASCT clinical practice [27,30]. Due toour previous success using MYXV to purge primary
human acute myeloid leukemia cells, the virus’ safety
for the engraftment of normal human HSPCs, and the
high rate of MM relapse after AHCT, we
hypothesized that ex vivo MYXV treatment might
represent an improved method for clinical elimination
of MM cells contaminating patient autograft samples
before reinfusion.MATERIALS AND METHODS
Cells and Reagents
U266 (American Type Culture Collection
[ATCC] #TIB-196), RPMI-8266 (ATCC# CCL-
155), MM.1S (ATCC# CRL-2974), and HuNS1
(ATCC# CRL-8644) human myeloma cells as well as
HL60 acute myeloid leukemia cells (ATCC# CCL-
240) were obtained from ATCC and were maintained
below 2 106 cells/mL in RPMI media supplemented
with 1 pen/strep, 2 mM L-glutamine, and 20% FBS.
The following Abs were used: HLA-A, HLA-B, HLA-
C-APC, CD45-PE, CD45-FitC, poly ADP-ribose
polymerase, HLA-A2.1-PE (BD Biosciences, San
Jose, CA), caspase 3 and cleaved caspase 3 (Cell Signal-
ing, Danvers, MA), and B actin (Ambion, Grand
Island, NY). Clinical-grade heparin (1,000 USP U/
mL) was a kind gift fromDr. Alexandra Lucas. Primary
MM cells were obtained by patient donation under the
approval of the University of Florida Institutional Re-
view Board.
MYXV and Viral Infections
vMyx-green fluorescent protein (GFP) has been
previously described [31]. Unless indicated, infections
were carried out by exposing cells to vMyx-GFP at
a multiplicity of infection (MOI) of 10 for 1 hour in
PBS 1 10% FBS in a humidified chamber at 37C
and 5% CO2. Mock-treated cells were incubated in
PBS 1 10% FBS containing no virus under the same
incubation conditions. Treatment with inactivated
virus was performed using the same incubation condi-
tions, but with inactivated vMyx-GFP prepared by ex-
posing virus to UV light for 2 hours (UV inactivated)
or incubating virus at 55C for 2 hours (heat inacti-
vated). Fluorescently tagged MYXV virions (vMyx-
M093L-Venus) were created by fusing the GFP
variant ‘‘Venus’’ protein in frame to the N-terminus
of the M093 open reading frame (to be described
elsewhere).
Analysis of MYXV Infection in Cultured
Myeloma Cells
To measure initiation of early viral gene expres-
sion, human myeloma cells were analyzed 24 hours
after infection with vMyx-GFP for expression of
GFP using flow cytometry. To measure completion
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fectious progeny virus, myeloma cells were harvested
at the indicated time points, pelleted, and frozen.
After harvesting, infectious virus was released by
sequential freeze-thaw, and the amount of virus in
each sample was determined as previously described
[32]. To measure the binding of MYXV to the cell sur-
face by flow cytometry, 1E9 vMyx-GFP virions were
incubated with 25 micrograms of cyclophosphamide
(Cy)5-NHS ester for 30 minutes at room temperature.
Unbound Cy5-NHS was removed by pelleting virions
at 13,000 rpm for 5 minutes and washing the resulting
pellet extensively with PBS. Cells were incubated with
MYXV-Cy5 at MOI 5 10 for 1 hour, washed exten-
sively, and analyzed by flow cytometry. For the bind-
ing of MYXV to primary MM patient BM samples,
vMyx-M093L-Venus was used as described in the
text. To measure the binding of MYXV to the cell
surface, myeloma cells were exposed to vMYX-GFP
at MOI 5 10 for 1 hour at 37C. Cells were then
washed 4 times with PBS 1 10% FBS. The contents
of the resulting pellet (virus) as well as the
supernatant from the last wash were then acid precip-
itated using trichloroacetic acid (final concentration
30%). Samples were resuspended in Laemmli buffer,
separated on a 15% acrylamide gel, and transferred
to polyvinylidene fluoride membrane. The presence
of viral proteins derived from MYXV virions was
then analyzed by standard immunoblot analysis using
an aMYXV rabbit polyclonal serum [33].
Myeloma Cell Viability and Proliferation Assays
Human myeloma cells were mock-treated or in-
fected with vMyx-GFP as previously mentioned.
For viability studies, 1  105 myeloma cells were
plated in triplicate into 96-well plates. Twenty-four
hours after treatment, cellular adenosine triphosphate
generation, which correlates with cell viability, was
measured using the commercial MTT assay (Pierce,
Rockford, IL) as per the manufacturer’s recom-
mended procedure. For cell proliferation studies,
1  104 myeloma cells were mock or vMyx-GFP
treated and plated in triplicate into 6-well dishes.
Cell density was analyzed every 24 hours by manually
counting trypan blue-excluding cells using a hemocy-
tometer.
MM Xenografts
For in vivo systemic engraftment studies, NOD/
Scid/IL2Rg2/2 (NSG) mice were sublethally irradi-
ated using 175 cGy total body irradiation from
a Cs137 source. Within 24 hours after irradiation,
mice were injected through the tail vein with 100 uL
PBS 1 10% FBS containing 1  106 MM cells, which
had been either mock-treated or infected with vMyx-
GFP at MOI 5 10. Prophylactic antibiotics wereadministered to animals in the drinking water for 2
weeks after transplantation to prevent opportunistic
bacterial infection. Two to 6 weeks after transplanta-
tion, mice were euthanized, and BM was harvested
from the right hind femur using a tuberculin syringe,
stained with Abs against human HLA-A, HLA-B, and
HLA-C, and analyzed using flow cytometry. Data are
presented as ‘‘level of engraftment,’’ which corresponds
to the percentage of HLA-A, HLA-B, and HLA-C1
cells in the BM of each mouse. Mice displaying any
level of HLA-A, HLA-B, and HLA-C1 cells were
scored as engrafted (C), whereas mice without any
detectable HLA-A, HLA-B, or HLA-C1 cells were
scored as nonengrafted (B). All animal experiments
were carried out under approved University of Florida
Institutional Animal Care and Use Committee proto-
col #2010-5023.
Mixing Experiments with Human Myeloma into
Normal Donor BM Samples
Fresh human BM aspirates were obtained com-
mercially from Lonza (Walkersville, Maryland). BM
mononuclear cells were then enriched over a Ficoll
gradient using a clinical Sepax device (Biosafe Inc.,
Lincolnshire, IL) as per manufacturer’s recommenda-
tions. CD341 human cells were fractionated from
Sepax-purified normal BM aspirates using the
CD341 microbead separation kit (Miltenyi Biotec,
Cambridge, MA) as per manufacturer’s recommenda-
tions. Cells were then separated on an autoMACS pro
separator (Miltenyi Biotec, Cambridge, MA) as per
manufacturer’s recommendations. The relative purity
of the fractionated population was confirmed after sep-
aration using flow cytometry. The total number of
fractionated cells was determined after separation us-
ing a hemocytometer. The 1  105 CD341 cells
were then mixed with 1  106 U266 myeloma cells.
U266 cells could be distinguished from normal hema-
topoietic cells based on their expression of HLA-A2.1
and CD138 as well as their lack of expression of CD45
and CD34.RESULTS
MYXV Infects and Kills Human MM Cell Lines
In Vitro
The therapeutic potential of oncolytic viruses
in vivo frequently correlates with their ability to selec-
tively infect and kill target cancer cells in vitro. We
therefore tested whether MYXV infected and killed 4
established human MM cell lines (U266, HuNS1,
MM.1S, andRPMI-8266) in vitro.Each cell linewas in-
cubated with vMyx-GFP, which expresses GFP from
a viral synthetic early/late promoter, at an MOI of 10.
After 24 hours of incubation, all 4 cell lines displayed
significant numbers of GFP1 cells (Figure 1A),
Figure 1. Rabbit-specific oncolytic poxvirus called myxoma virus (MYXV) infects and kills multiple human multiple myeloma (MM) cell lines in vitro. (A)
Each of the 4 human MM cell lines tested was infected with vMyx-green fluorescent protein (GFP) at multiplicity of infection (MOI)5 10. Twenty-four
hours later, the percent of cells expressing GFP was quantified using flow cytometry. (B) Each MM cell line was mock-treated or infected with vMyx-GFP,
and the cellular viability was measured 24 hours after infection using the commercial MTTassay. (C) Each MM cell line was mock-treated or infected with
vMyx-GFP, and the number of trypan blue-excluding cells was determined at the indicated times using a hemocytometer.
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tions in all 4 cell lines. Additionally, treatment
with vMyx-GFP significantly reduced the cellular
viability, asmeasured by theMTTmitochondrial func-
tion assay, of all 4 cell lines (Figure 1B) and completely
abrogated subsequent cellular proliferation in culture
(Figure 1C).Ex Vivo MYXV Treatment Inhibits In Vivo
Systemic Engraftment of MM Cell Lines into
NSG Mice
To determine if ex vivoMYXV treatment could in-
hibit systemic engraftment of MM cells in vivo, 4
human MM cell lines were mock-treated or treated
with vMyx-GFP ex vivo and then transplanted i.v.
into sublethally irradiated immunodeficient NSG
mice. Two to 6 weeks after transplantation, the
animals were analyzed for human MM in femurs.
Engrafted human MM cells were readily observed in
the BM of mice transplanted with mock-treated
RPMI-8266 cells (9 of 10 mice positive, average
human myeloma engraftment in mouse BM 5
6.2%), MM.1S cells (all of 10 mice positive,
average 5 75.7%), HuNS1 cells (all of 10 mice posi-
tive, average 5 34.5%), and U266 cells (9 of 10 mice
positive, average 5 35.0%), demonstrating that all 4MMcell lines effectively xenografted into NSGmouse
BM (Figure 2). In contrast, no human MM cells were
detected in the BM of mice transplanted with
MYXV-treated RPMI-8266, HuNS1, or U266 cells
and were only observed at a very low level (0.1%) in
1 of the 10 mice injected with MYXV-treated
MM.1S cells. Additionally, mice transplanted with
MYXV-treated cells did not develop any symptoms
of clinicalMM, which were routinely observed 2 weeks
after injection of mock-treated HuNS1 and 5 weeks
after injection of mock-treated U266 cells (our unpub-
lished observations).MYXV Specifically Eliminates MM Cells while
Sparing Normal Hematopoietic Stem Cells
One of the major challenges associated with auto-
graft purging is specifically eliminating contaminating
cancer cells while sparing the normal HSPCs required
for reconstitution of the patient’s hematopoietic sys-
tem. Therefore, to determine if MYXV treatment
distinguished human MM cells from normal HSPCs,
we treated mixtures of U266 cells and primary human
HSPCs with vMyx-GFP and then analyzed GFP ex-
pression in both populations of cells after 24 hours. In
these experiments, U266 cells can be distinguished
fromHSPCsbased on expressionof the surfacemarkers
Figure 2. Rabbit-specific oncolytic poxvirus calledmyxoma virus (MYXV) inhibits systemic engraftment of human multiple myeloma (MM) cell lines into
immunodeficient NOD/Scid/IL2Rg2/2 (NSG) mice. Each human MM cell line was mock-treated or treated with MYXV at multiplicity of infection
(MOI) 5 10 (n 5 10) and then injected i.v. into NSG mice. Two weeks (HuNS1) or 6 weeks (RPMI-8266, MM.1S, U266) after injection, bone marrow
(BM) was harvested from each mouse, stained with Abs against human HLA-A, HLA-B, and HLA-C, and analyzed using flow cytometry. Data are pre-
sented as ‘‘level of engraftment,’’ which corresponds to the percent of HLA-A, HLA-B, and HLA-C1 cells in the BM of each mouse. Mice displaying any
level of HLA-A, HLA-B, and HLA-C1 cells were scored as engrafted (C), whereas mice without any detectable HLA-A, HLA-B, or HLA-C1 cells were
scored as nonengrafted (B).
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CD34 (U266 cells are HLA-A, HLA-B, HLA-C1/
HLA-A2.11/CD452/CD342 whereas human HSPCs
are HLA-A, HLA-B, HLA-C1/HLA-A2.12/CD451/
CD341). Expression of GFP, indicating the initiation
of viral infection, was observed in a significant percent-
age of HLA-A2.11 U266 cells (45.9%). In contrast,
expression of GFP was observed in less than 5% of
the CD341 cell population (Figure 3A).
To confirm that MYXV treatment functionally
discriminated MM cells from normal HSPCs,
mixtures of U266 cells and primary human CD341
HSPCs were mock-treated or treated with vMyx-
GFP and then transplanted into sublethally irradiated
NSG mice. Six weeks after transplantation, engraft-
ment of both U266 cells and repopulating human
leukocytes derived from HSPCs were analyzed
using flow cytometry. In mice transplanted with
mock-treated mixtures, coengraftment of both U266
cells as well as HSPCs was readily observed
(Figure 3B). In contrast, mice injected with MYXV-
treated mixtures failed to display detectable engraft-
ment of U266 cells, while exhibiting engraftment of
HSPCs at levels identical to mock-treated samples.
Together, these results indicate thatMYXV effectively
discriminates between MM cells and normal HSPCs
found in the same graft sample and purges the MM
cells while sparing the normal HSPCs allowing
efficient hematopoiesis.MYXVElimination of HumanMMCells Requires
Direct Virion Binding
We recently discovered that the ability of MYXV
to purge acute myeloid leukemia cells necessitates viral
binding to the cell surface [34]. We therefore tested
whether MYXV also required direct adsorption of
the virus particles in order to eliminate MM cells.U266 cells were treated with vMyx-GFP in either
the presence or absence of soluble heparin, which in-
hibits poxvirus binding to mammalian cells by coating
the positively charged virion [35] (and our unpublished
observations). After 24 hours, a high percentage of
U266 cells incubated in the absence of heparin
displayed GFP expression, whereas virtually no
GFP1 cells could be identified in samples incubated
in the presence of heparin (Figure 4A). The presence
of heparin during infection also largely abrogated the
ability of MYXV to reduce cellular viability (data not
shown) and prevent subsequent cellular proliferation
(Figure 4B). Finally, to determine if virion binding
was required for MYXV to inhibit engraftment of
MM cells in vivo, U266 cells were incubated with
vMyx-M093L-Venus in either the presence or absence
of soluble heparin and then transplanted i.v. into NSG
mice. Consistent with our previous results, mice
transplanted with mock-treated U266 cells displayed
a high number of human cells engrafted in the BM 6
weeks after transplantation, whereas these cells could
not be detected in mice transplanted with ex vivo
MYXV-treated cells. In contrast, engrafted human
cells were readily detectable in the BM of mice trans-
planted with cells treated with MYXV in the presence
of soluble heparin (Figure 4C) suggesting that effective
purging requires MYXV binding to the target MM
cancer cell.MYXV does not Bind to Normal Human HSPCs
Due to this result, we hypothesized that MYXV
might spare normal human HSPCs due to a failure
of these cells to support virion binding. To test this,
primary human BM was mixed with U266 cells or
HL60 cells, an acute myeloid leukemia cell line, which
is unable to support MYXV binding (our unpublished
observations) and then incubated with MYXV-Cy5
Figure 3. Rabbit-specific oncolytic poxvirus called myxoma virus (MYXV) eliminates human multiple myeloma (MM) cells while sparing normal primary
human hematopoietic stem cells. (A) U266 cells were mixed at a 10:1 ratio with donor human bone marrow (BM)-derived CD341 hematopoietic stem
and progenitor cells (HSPCs). Mixtures were then mock-treated or infected with vMyx-green fluorescent protein (GFP) at multiplicity of infection
(MOI)5 10 for 24 hours, and expression of GFP was analyzed using flow cytometry. Events shown are gated on live HLA-A2.11 (Top) or CD341 (Bot-
tom) cells. Inset number indicates the percent of GFP2 andGFP1 cells. (B) U266 cells weremixed at a 10:1 ratio with purified human BM derived CD341
HSPCs. Mixtures were then mock-treated or infected with vMyx-GFP at MOI 5 10 and injected i.v. into NOD/Scid/IL2Rg2/2 (NSG) mice. Six weeks
after injection, BM was harvested from each mouse, stained with Abs against human HLA-A, HLA-B, HLA0C, human HLA-A2.1, and human CD45 and
analyzed using flow cytometry. U266 cells were identified as staining HLA-A, HLA-B, HLA-C1/HLA-A2.11/CD452, while progeny derived from normal
HSPCs were identified as staining HLA-A, HLA-B, HLA-C1/HLA-A2.12/CD451. Data are presented as ‘‘level of engraftment,’’ which corresponds to the
percent of HLA-A, HLA-B, HLA-C1/HLA-A2.11, or HLA-A, HLA-B, HLA-C1/CD451 cells in the BM of eachmouse. Mice displaying any level of positive
cells were scored as engrafted (C), while mice without any detectable positive cells were scored as nonengrafted (B).
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on U266 cells, HL60 cells, or primary CD341HSPCs
was analyzed using flow cytometry (Figure 4D).While
theMYXV-purgeable U266 cells displayed a high levelof Cy5 florescence, corresponding to efficient MYXV
virion binding, only low levels of Cy5 florescence
were detected on the MYXV-nonpurgable HL60 cells
and CD341 HSPCs supporting the hypothesis that
Figure 4. Rabbit-specific oncolytic poxvirus called myxoma virus (MYXV)-based killing of human multiple myeloma (MM) cells in vitro requires virion
binding. (A) U266 cells were infected with vMyx-green fluorescent protein (GFP) at multiplicity of infection (MOI) 5 10 in either the presence or ab-
sence of 5% soluble heparin. Twenty-four hours later, the percent of cells expressing GFP was quantified using flow cytometry. (B) U266 cells were
infected with vMyx-GFP at MOI 5 10 in either the presence or absence of 5% soluble heparin, and the number of trypan blue-excluding cells was de-
termined at the indicated times using a hemocytometer. (C) U266 cells were mock-treated or treated with vMyx-GFP in either the presence or absence
of 5% soluble heparin and then injected i.v. into NOD/Scid/IL2Rg2/2 (NSG) mice. Six weeks after injection, bonemarrow (BM) was harvested from each
mouse, stained with Abs against human HLA-A, HLA-B, and HLA-C and analyzed using flow cytometry. Data are presented as ‘‘level of engraftment,’’
which corresponds to the percent of HLA-A, HLA-B, and HLA-C1 cells in the BM of each mouse. Mice displaying any level of HLA-A, HLA-B, and HLA-
C1 cells were scored as engrafted (C), while mice without any detectable HLA-A, HLA-B, and HLA-C1 cells were scored as nonengrafted (B). Inset
depicts the binding of MYXV virions in the presence or absence of soluble heparin as detected by immunoblot using an aMYXV polyclonal antiserum. (D)
U266 cells (red), HL60 cells (blue), or normal CD341 stem cells (green) were incubated with MYXV-cyclophosphamide (Cy)5 for 1 hour and then
washed extensively. Cy5 florescence (indicating virion binding) was then analyzed using flow cytometry and compared to mock-treated cells (black).
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not support MYXV virion binding.MYXV Kills Human MM Cells by Rapidly
Inducing Apoptosis
Frequently, oncolytic viruses eradicate their
targets through direct lytic replication; we therefore
asked whether this mechanism was responsible for
MYXV-based elimination of MM cells. Each of our
4 human MM cell lines was incubated with MYXV at
MOI 5 1, and the replication of new infectious viral
progeny was measured using single-step viral growth
analysis. Surprisingly, we observed that even though
MYXV effectively initiated infection and killed all 4MM cell lines, no new viral progeny were created dur-
ing this process (Figure 5A). Additionally, treatment of
human MM cells with replication-incompetent
MYXV, which had been UV-inactivated, reduced cel-
lular viability and proliferation comparably to treat-
ment with live virus (Figure 5B, C). In contrast,
treatment with heat-inactivated MYXV did not affect
MM cell viability or proliferation.
Because our data suggested that MYXV kills
human MM cells via a mechanism that is not depen-
dent on lytic viral replication, we next determined
the cause of MYXV-induced MM cell death. A pheno-
typic examination of MM cells treated with MYXV re-
vealed that these cells rapidly displayed membrane
blebbing, a process frequently associated with
Figure 5. Rabbit-specific oncolytic poxvirus called myxoma virus (MYXV) kills human multiple myeloma (MM) cells in vitro by inducing rapid apoptosis.
(A) Each human MM cell line was infected with vMyx-green fluorescent protein (GFP) at multiplicity of infection (MOI)5 1. At the indicated times, cells
were harvested and frozen. After all time points had been collected, cells were lysed using repeated freeze-thaw, and the amount of infectious virus in
each sample was quantitated using foci formation on BSC40 cells. (B) U266 cells were either mock-treated or infected with live vMyx-GFP, heat-inacti-
vated vMyx-GFP, or UV-inactivated vMyx-GFP at an apparent MOI 5 10. After 24 hours, cellular adenosine triphosphate generation, which correlates
with the number of living cells, was measured using the commercial MTTassay. (C) U266 cells were mock-treated or infected with live, heat, or UV-
inactivated vMyx-GFP, as described above, and the number of trypan blue-excluding cells was determined at the indicated times using a hemocytometer.
(D) U266 cells were mock-treated or infected with live, heat, or UV-inactivated vMyx-GFP, as defined above, and then cellular morphology was observed
24 hours after infection using a Leica DMI 6000B light microscope. (E) U266 cells were mock-treated or infected with live, heat, or UV-inactivated vMyx-
GFP, as described above. Cells were harvested at the indicated time points, and whole cell lysates were assayed with the indicated Abs via immunoblot.
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treated with either live or UV-inactivated MYXV dis-
played cleavage of the apoptotic effector, caspase-3, as
well as cleavage of poly (ADP-ribose) polymerase,
a marker for late-stage apoptosis (Figure 5E). We
therefore conclude that MYXV kills human MM cells
by inducing rapid cellular apoptosis that is triggered so
quickly that it aborts the virus replication cycle before
the generation of progeny virus.MYXV Infects Primary Human CD1381
Myeloma Cells Contaminating Patient BM
Immortalized cell lines frequently exhibit pheno-
types significantly different from primary cancer cells
analyzed directly ex vivo. We therefore tested whetherMYXV targeted and eliminated primary CD1381MM
cells contaminating primary patient BM samples.
Three BM samples from different patients with mye-
loma were mock-treated or incubated with vMyx-
M093L-Venus (which expresses the GFP variant
‘‘Venus’’ protein fused in-frame to the major structural
protein M093, thus causing the virion particle to in-
corporate high levels of Venus that can be detected
by flow cytometry). Immediately after viral adsorption,
primary CD1381MM cells from all 3 patient samples
exhibited Venus florescence comparable to U266 cells
(Figure 6A Top) indicating that MYXV bound to pri-
mary CD1381MM cells and established myeloma cell
lines at similar levels. Consistent with our previous
results, virtually no Venus florescence was observed
in the CD341 HSPC compartment from the same
Figure 6. Rabbit-specific oncolytic poxvirus called myxoma virus (MYXV) effectively eliminates CD1381 cells from primary multiple myeloma (MM)
patient samples. (A) Primary bone marrow (BM) from 3 patients with MM was mock-treated or incubated with vMyx-M093L-Venus at multiplicity of
infection (MOI) 5 10 for 1 hour, stained with Abs against either CD138 (A) or CD34 (B), and then washed extensively. Virus produced by vMYX-
M093L-Venus incorporates high levels of Venus into the virion and can be used to quantify virion binding by flow cytometry. Venus florescence from
mock-treated (black line) as well as vMyx-M093L-Venus treated (red line) samples was then analyzed using flow cytometry at 0 hours and 24 hours after
adsorption. Data from normal BM mixed with U266 cells are shown as a comparison.
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numbers of CD1381MM cells could still be found in
all 3 mock-treated samples, whereas virtually no con-
taminating CD1381 cells remained in any patient sam-
ple, which had been treated with MYXV (Figure 6A
Bottom). Significantly, the few CD1381 cells that still
persisted after 24 hours displayed high levels of Venus
fluorescence indicating they were undergoing activeMYXV infection. In contrast, the number of CD341
stem cells was unaffected by MYXV treatment, and
relatively few of these cells displayed any evidence of
viral infection (Figure 6B Bottom). Unfortunately,
our repeated attempts to engraft primary human
MMsamples intoNSGmice resulted in little or no sta-
ble engraftment even in mock-treated controls, and so
we were unable to document the in vivo efficacy of
Biol Blood Marrow Transplant 18:1540-1551, 2012 1549Myxoma Virus Purges Multiple MyelomaMYXV treatment at inhibiting engraftment of primary
myeloma. However, our data clearly demonstrate
that MYXV infects and eliminates U266 cells and
primary CD1381 MM cells in vitro with similar effi-
cacy in the context of BM samples from patients with
myeloma.DISCUSSION
We describe a novel method to eliminate human
MM cells from autologous HSPC samples ex vivo
using an oncolytic virus, MYXV, which selectively
targets MM cells but does not bind or infect normal
human CD341 stem cells. MM disease relapse after
ASCT may arise from 2 sources: residual disease
sequestered in bone niches that failed to be elimi-
nated by the myeloablative chemotherapy and/or
low levels of MM cells that contaminate the HSPC
graft. However, previous studies have shown that
the prognosis for patients with MM does correlate
with the level of contamination in stem cell product
used for transplantation [6-8] and that patients
treated with syngeneic transplantations from
identical twin donors achieve considerably better
rates of disease remission and prolonged survival
[9-11]. This strongly indicates that clinical outcomes
will be improved if a method can be developed
that quantitatively eliminates all contaminating MM
cells from autologous HSPC samples. These
observations have led to a variety of other methods
being explored for purging MM cells from autograft
samples, most notably positive selection of CD341
HSPCs. Unfortunately, CD341 positive selection-
based purging strategies have not proven clinically
effective [18,19]. Although the reason for these
failures is not fully known, it has been
demonstrated that CD341 stem cell selection is
unable to completely eliminate all MM cells
contaminating ASCT products [22]. Additionally, pa-
tient samples can contain a CD341 clonal cell popu-
lation related to the patient with MM that cannot be
eliminated by CD341 enrichment. These data sug-
gest that, although MM purging in general might
be clinically beneficial, CD341 stem cell enrichment
is unable to completely eradicate disease-causing MM
cells from HSPC samples. Alternatively, it is possible
that the major cause of myeloma relapse after ASCT
is residual disease persisting in the patient after abla-
tive chemotherapy. Therefore, novel MM purging
strategies that are not based on positive CD341
stem cell selection, particularly a procedure also capa-
ble of treating residual disease, are needed.
Our data demonstrate the effectiveness of onco-
lytic MYXV as a selective purging agent for human
MM cells both in vitro and in vivo. Several other
groups have recently published purging strategies
for various malignancies based on other oncolytic vi-ruses, including adenovirus, vesicular stomatitis
virus, herpes simplex virus, and reovirus (reviewed
in [36,37]). Although many of these viral
treatments were effective in vitro, to date, only 3
have demonstrated purging efficacy in vivo [38-40].
Unfortunately, all 3 of these previously described
viral purging strategies required the stem cell
transplantation graft to be incubated ex vivo for
long periods of time and then treated with
cytotoxic chemotherapeutics before transplantation,
limiting applicability to clinical translation. In
contrast, the MYXV-based ex vivo purging strategy
described here demonstrates excellent efficacy
against human MM both in vitro and in vivo, did
not harm the engraftment potential of normal
HSPCs, and required minimal ex vivo manipulation
of the autograft before transplantation. Therefore,
this study represents the first report of an effective
viral ex vivo purging strategy that demonstrates effi-
cacy at preventing relapse in the in vivo models and
can be easily translated to the clinic. Additionally,
the absence of documented cases of MYXV infection
in any non-rabbit species, including humans or mice,
suggests that MYXV possesses an excellent safety
profile for in vivo use.
Interestingly, although MYXV treatment had
a profound effect on long-term MM growth both in-
vitro and in vivo, evidence of direct viral infection, as
measured by GFP expression from an encoded trans-
gene, was only observed in 50% to 70% of treated
cells (Figure 1). This could be related to the limita-
tions in detecting GFP fluorescence or to the ability
of MYXV to eliminate MM cells through a mecha-
nism independent of viral replication. For example,
epitopes on the MYXV virion may act as functional
ligands that trigger the rapid activation of a cell sur-
face death receptor on MM cells, such as those of the
TNF-receptor superfamily. This second direct-
killing hypothesis is supported by the observation
that U266 cells treated with MYXV at MOIs as low
as 0.1 universally undergo apoptosis and fail to
engraft into NSG mice (data not shown). Impor-
tantly, the observed MYXV-induced reductions in
cellular viability and levels of direct infection were
similar in both the 4 established human MM cell lines
as well as all 3 primary patient samples, and these
levels of MM cell depletion translated into significant
clinical benefit in vivo in terms of the ability to pre-
vent engraftment of the MYXV-treated MM cell
lines. These data collectively suggest that ex vivo
MYXV treatment will be efficacious in reducing
relapse rates of MM caused by infusion of contami-
nated ASCT samples.
It is believed that residual MM cells persisting in
the patient’s BM despite myeloablative chemotherapy
also play a major role in patient disease relapse. Inter-
estingly, systemic injection of oncolytic vaccinia virus
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in humans [41], whereas injection of oncolytic mea-
sles virus bound to MM carrier cells has been shown
to effectively treat established MM in murine models
[42,43]. Additionally, it has been demonstrated that
treatment with a variety of oncolytic viruses can
result in elimination of residual cancer cells from
therapy-resistant niches by redirecting the immune
system to more effectively recognize tumor antigens
[44,45]. While still untested, it should be noted that
because of the potent MM cell death induced by
cell contact with this virus, the MYXV-based purging
strategy described here also has the potential to treat
established MM, which is resistant to current therapy
through all these mechanisms. Alternatively, systemic
injection of MYXV might also be used to directly
treat residual myeloma that has resisted the primary
myeloablative chemotherapy. In our preliminary ex-
periments, such treatments can have promising effi-
cacy in mouse models of pre-established myeloma
(our unpublished observations). Significant issues,
such as developing an optimal strategy to deliver virus
to all potential myeloma niches in vivo, remain to be
addressed. Despite these limitations, however, we
propose that MYXV-based virotherapy, either as an
ex vivo MYXV-based purging protocol or possibly
augmented by systemic viral injection, has the poten-
tial to treat both MM-contaminated autografts as
well as in vivo residual MM, which persists after ab-
lative therapy. Interestingly, since UV-inactivated
and live-MYXV showed similar in vitro efficacy at in-
ducing apoptosis in MM cells, it is possible that com-
pletely replication-incompetent virus could also be
used to eliminate MM cells contaminating the
ASCT grafts. This would create an even safer clinical
purging agent and alleviate any ethical concerns
associated with injection of live virus.
Significantly, we demonstrate that when normal
primary CD341 human HSPCs are admixed with
human MM cells, the resulting mixture causes en-
graftment of both normal HSPCs and MM cells in
the BM of NSG mice. However, in stark contrast,
when these same mixtures are treated ex vivo with
MYXV, only the normal HSPCs successfully engraft
into the recipients, while the contaminating MM cells
are selectively purged. This specificity seems to be
due to the selective binding of MYXV to MM cells
but not to primary CD341 HSPCs. Interestingly,
poxviruses like MYXV are extremely promiscuous
in their binding to relatively conserved glycosamino-
glycans, effectively attaching to a broad spectrum of
mammalian cells [46].
In conclusion, our data show that ex vivo MYXV
treatment of autografts contaminated with MM is
safe and effective in preclinical models of human
MM. Results from this work support the translation
of this novel purging method to the clinic.ACKNOWLEDGMENT
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